Lumen is a biotechnology company focused on synthetic biology, protein design, and immunology to create a portfolio of biologic therapies and scientific discoveries.

Lumen

Simris Biologics identifies and develops applications for novel, natural biologics sourced from cyanobacteria and microalgae. The company develops technology platforms based on these compounds and partners with customers to create final products.

Simris Biologics

Lumen Bioscience develops oral antibody therapeutics.

U.S. Department of Defense

U.S. Army Medical Research & Development Command

Medical Technology Enterprise Consortium

CARB-X

US Department of Energy

Avista Development

Bioeconomy Capital

WestRiver Group

Columbia Pacific Advisors

Lumen Bioscience

Brian Finrow discusses how the forever war against human #microbial pathogens desperately needs #innovation, but fresh thinking is needed to restore the R&D pipeline. #drugdevelopment

https://lnkd.in/ezHuy92R

We are pleased to announce $5.5 million in new funding from the U.S. Department of Defense, operating through the Medical CBRN Defense Consortium (MCDC), to develop enabling technologies for needle-free vaccines. This new technology could expand access and ease vaccine production, storage, and administration in future public health emergencies.

Read the announcement below,

https://lnkd.in/gEPvt65J

#needlefree #vaccine #seattle #wa #fundingnews #mcdc #biotech #publichealth #vaccinedevelopment

"The antibiotics crisis is a silent pandemic that threatens to knock modern society back into the medieval age of therapeutic leaches and serum therapy."

Check out Brian Finrow's (Lumen, CEO) new opinion piece in STAT on why scalable, preventive biologic drugs sidestep the market failure issues that block bedevil conventional antibiotics development.

Read below, 

#statnews #lumenbio #seattle #wa #biotech #biologics #biologicdrugs #antibiotics #article

https://lnkd.in/gMF3qVQ9

We are pleased to announce a $16.2 million award by the U.S. Department of Defense to advance LMN-201 through late-stage trials. LMN-201 is an investigational, orally delivered biologic drug to treat and prevent C. difficile infection (CDI).

Read the full release below, 

#cdiff #lumenbio #seattle #wa #clinicaltrial #biotech

https://lnkd.in/gyE_E6tN

Metric
Company Name	Lumen	Simris Biologics
Symbol
MSH ID	BIO:LUMEN	COM:SIMRISBIOLOGICS
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	SE
Stage
Employee Count	68
Website	lumen.bio	simrisbiologics.com
LinkedIn	lumen-bioscience
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		88
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

BIO:LUMEN

Lumen

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue